Wegovy contains semaglutide, a prescription medicine that acts on GLP-1 receptors involved in appetite regulation. The US prescribing information and the European product information describe both tablets and injections for weight management alongside dietary changes and physical activity. The European information specifies tablets for adults. The approved indication depends on the formulation, age group and jurisdiction. [1] [2]
How much weight did participants lose with the tablet?
OASIS 4 enrolled 307 adults without diabetes who had obesity or overweight with a related health condition. Both groups received lifestyle support. At 64 weeks, the estimated average weight loss was 13.6% with oral semaglutide and 2.2% with placebo. These percentages describe changes from each group’s starting weight. Individual responses varied. The study compared the tablet with placebo and did not directly compare tablets with injections. [3]
Who had fewer cardiovascular events?
SELECT studied injectable semaglutide in 17,604 adults aged 45 or older with established cardiovascular disease, a body mass index of at least 27 and no history of diabetes. During an average 39.8 months of follow-up, 6.5% in the semaglutide group and 8.0% in the placebo group experienced a cardiovascular death, nonfatal heart attack or nonfatal stroke. The observed difference was about 15 fewer people per 1,000. Applying that figure to people without established cardiovascular disease would exceed the evidence from this trial. [4]
What should the prescribing discussion cover?
The review should cover other medicines, pregnancy plans, gastrointestinal symptoms and any upcoming procedure. Nausea and vomiting are common. Severe persistent abdominal pain warrants prompt assessment for pancreatitis. The US label lists a personal or family history of medullary thyroid carcinoma and multiple endocrine neoplasia type 2 as contraindications. Because semaglutide can delay stomach emptying, the anaesthesia team needs to know about its use before general anaesthesia or deep sedation. [1] [2]
What to take into practice
For a treatment discussion, identify the exact product and the outcome that matters. OASIS 4 measured weight change with tablets. SELECT tested cardiovascular outcomes with injections in people who already had cardiovascular disease. [3] [4]
Sources
Evidence checked on 21 November 2026.
[1] US Food and Drug Administration — Wegovy prescribing information (2026-06).
[2] European Medicines Agency — Wegovy EPAR and product information (2026-10-26).
[3] Wharton S et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. New England Journal of Medicine (OASIS 4). (2025-09-17).
[4] Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine (SELECT). (2023-11-11).